Anavex life sciences to present at the h.c. wainwright virtual bioconnect conference

New york, jan. 06, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will present at the h.c. wainwright virtual bioconnect conference being held from january 11-14, 2021.
AVXL Ratings Summary
AVXL Quant Ranking